- Home
- NVNI vs MAIA Comparison
NVNI vs MAIA Comparison
Compare NVNI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVNI | MAIA |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | Brazil | United States |
| Employees | 618 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 49.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | NVNI | MAIA |
|---|---|---|
| Price | $1.31 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.87 |
| 52 Week High | $4.94 | $3.19 |
Technical Indicators
Market Signals| Indicator | NVNI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 39.39 |
| Support Level | $1.10 | $1.20 |
| Resistance Level | $1.64 | $1.66 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 46.87 | 16.67 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.